Asinex and Recordati announce an integrated drug discovery collaboration in the area of micturition disorders
The first phase of the collaboration consists of the design by Asinex of several unique new chemical structures and the creation of a library of new candidate compounds for the potential treatment of overactive bladder.
The second phase will be the synthesis of these structures, which will be followed by a final round of optimisation.
Asinex's aim is to provide Recordati, to whom all intellectual property rights will belong, with patentable candidate series.
Avi Sartani, VP pharmaceutical R and D and licensing at Recordati, said: "The collaboration with Asinex allowed Recordati to select new chemical structures of interest for its drug discovery programmes.
"The collaboration is now continuing with the synthesis of new lead compounds, that will be tested in our laboratories.
"We are looking forward to continuing the collaboration with Asinex all the way through to candidate selection and optimisation". Dmitry Genis, Asinex's CEO, stated: "We are very pleased to announce the success of our first integrated drug discovery project, and are delighted that Recordati has decided to enlarge the collaboration to the library synthesis and optimisation stage.
"Once again, Asinex's technology platform has proved to be a creative tool to design unique small molecules drug candidates for protein targets.
"We are determined to provide Recordati with a high value set of lead compounds and to establish a long-term relationship".
